VIVUS, Inc. (VVUS)
(Delayed Data from NSDQ)
$3.73 USD
+0.03 (0.81%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.83 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.73 USD
+0.03 (0.81%)
Updated May 3, 2019 04:13 PM ET
After-Market: $3.83 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
VIVUS (VVUS) Banks on New Drug Pancreaze, Qsymia Lacks Luster
by Zacks Equity Research
Although VIVUS (VVUS) is struggling with its legacy products, promotional initiatives and addition of cash-flow positive assets bode well for the company.
5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride
by Kinjel Shah
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.
New Strong Buy Stocks for December 7th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Vivus (VVUS) Down 17% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Vivus (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y
by Zacks Equity Research
VIVUS (VVUS) reports narrower-than-expected loss in the third quarter. Sales increase year over year.
Why Is Vivus (VVUS) Down 6.4% Since Last Earnings Report?
by Zacks Equity Research
Vivus (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
VIVUS' (VVUS) Qsymia Falters in a Highly Competitive Market
by Zacks Equity Research
VIVUS' (VVUS) Qsymia sales lackluster due to slow uptake of the drug and a competitive market.
VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y
by Zacks Equity Research
VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.
VIVUS' PAH Candidate Data Positive in Early Stage Study
by Zacks Equity Research
VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.
VIVUS, Inc. (VVUS) Soars: Stock Adds 10.1% in Session
by Zacks Equity Research
VIVUS (VVUS) was a big mover last session, as the company saw its shares rise more than 10% on the day, amid huge volumes.
Can The Uptrend Continue for VIVUS (VVUS)?
by Zacks Equity Research
Investors certainly have to be happy with VIVUS, Inc. (VVUS) and its short term performance
3 Biotech Stocks Up in the Past Month on Industry Turnaround
by Zacks Equity Research
We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.
VIVUS (VVUS) in Focus: Stock Moves 5.6% Higher
by Zacks Equity Research
VIVUS (VVUS) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters
by Zacks Equity Research
VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.
Why Is VIVUS (VVUS) Down 18% Since its Last Earnings Report?
by Zacks Equity Research
VIVUS (VVUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Orexigen Struggles as Contrave Commercialization Costs Rise
by Zacks Equity Research
Orexigen (OREX) hurt by higher commercialization costs related to Contrave.
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down
by Zacks Equity Research
VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.
Orexigen's (OREX) Contrave Sales Improving on Promotions
by Zacks Equity Research
Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.
VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug
by Zacks Equity Research
VIVUS, Inc. (VVUS) signed an agreement with Alvogen giving rights to the latter to market anti-obesity drug Qsymia in Korea for the treatment of chronic weight management or weight-related conditions.
VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
VIVUS (VVUS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y
by Zacks Equity Research
VIVUS reported dismal second-quarter results wherein its loss widened from the year-ago period on lower sales.
VIVUS Settles with Teva on Weight Management Drug Generic
by Zacks Equity Research
VIVUS, Inc. (VVUS) announced that it has entered into a settlement agreement with Teva Pharmaceutical Industries Limited (TEVA), thereby resolving a three-year old patent litigation related to its weight management drug Qsymia.
BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).
Why is Corcept's Stock Up More Than 60% So Far This Year?
by Zacks Equity Research
Shares of Corcept Therapeutics Incorporated (CORT) has soared 62.5% this year so far, massively outperforming the 5.6% increase registered by the Zacks classified Medical Drugs industry during this period.
Roche (RHHBY) Launches Cobas Test for Bacterial Infections
by Zacks Equity Research
Roche Holdings AG (RHHBY) launched CE-IVD, the cobas MRSA/SA nucleic acid test be used on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant MRSA and SA at the point of care.